Compare DexCom, Inc. (DXCM) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Yum China Holdings Inc — how do they compare? DexCom, Inc. trades at $77.61 (market cap $28.06B), while Yum China Holdings Inc trades at $44.42 (market cap $14.84B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Yum China Holdings Inc pays a 2.69% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | YUMC | |
|---|---|---|
Market Cap | $28.06B | $14.84B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $57.95 |
52-Week Low | $54.84 | $40.18 |
Enterprise Value | $27.03B | $15.73B |
Dividend Yield | — | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Yum China Holdings (YUMC) trades at $43.30, down 1.37% today, with a bullish technical signal supported by moving averages. The company shows consistent revenue growth from $9.6B in 2022 to $11.8B in 2025, with net income reaching $929M. Recent strategic moves include acquiring full ownership of Pizza Hut in mainland China and announcing a $1.5B capital return plan for 2026. Valuation metrics appear reasonable with P/E of 16.54 and P/S of 1.3.
YUMC presents a compelling investment case with strong analyst support (74% buy ratings), consistent earnings beats, and strategic expansion in China's QSR market. Key risks include Chinese consumer spending volatility and intense competition. The upcoming Q2 2026 earnings report on July 30 will be crucial for validating growth trajectory amid ongoing market challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
